Indira Brar

4.1k total citations · 2 hit papers
56 papers, 1.6k citations indexed

About

Indira Brar is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Indira Brar has authored 56 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Infectious Diseases, 17 papers in Epidemiology and 14 papers in Virology. Recurrent topics in Indira Brar's work include HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (13 papers) and COVID-19 Clinical Research Studies (11 papers). Indira Brar is often cited by papers focused on HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (13 papers) and COVID-19 Clinical Research Studies (11 papers). Indira Brar collaborates with scholars based in United States, United Kingdom and Spain. Indira Brar's co-authors include Hal Martin, Geehan Suleyman, Raef Fadel, George Alangaden, Carina Dagher, Zachary Demertzis, Kelly Malette, Mayur Ramesh, Joseph Miller and Marcus Zervos and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Indira Brar

48 papers receiving 1.5k citations

Hit Papers

Clinical Characteristics and Morbidity Associated With Co... 2017 2026 2020 2023 2020 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit
    2020 456 citations Geehan Suleyman, Indira Brar et al. profile →
  2. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
    2017 257 citations Joel E. Gallant, Adriano Lazzarin et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Indira Brar United States 15 1.1k 449 361 330 238 56 1.6k
Elena Seminari Italy 20 847 0.8× 457 1.0× 239 0.7× 297 0.9× 111 0.5× 87 1.2k
Justyna Kowalska Poland 18 1.4k 1.3× 519 1.2× 925 2.6× 868 2.6× 104 0.4× 100 2.2k
Ian Woolley Australia 28 1.0k 0.9× 619 1.4× 738 2.0× 596 1.8× 50 0.2× 128 2.4k
Barry S. Zingman United States 20 985 0.9× 438 1.0× 345 1.0× 652 2.0× 18 0.1× 57 1.6k
Antoni Noguera‐Julián Spain 20 821 0.7× 328 0.7× 362 1.0× 655 2.0× 71 0.3× 125 1.5k
Giuseppe Vittorio De Socio Italy 23 834 0.7× 370 0.8× 859 2.4× 411 1.2× 27 0.1× 109 1.6k
Marco Floridia Italy 19 935 0.8× 373 0.8× 334 0.9× 362 1.1× 38 0.2× 99 1.2k
É. Rouveix France 15 464 0.4× 184 0.4× 123 0.3× 458 1.4× 28 0.1× 77 948
Thierry May France 21 757 0.7× 330 0.7× 404 1.1× 976 3.0× 23 0.1× 40 1.8k
Javier Martínez‐Sanz Spain 18 401 0.4× 112 0.2× 98 0.3× 425 1.3× 87 0.4× 82 903

Countries citing papers authored by Indira Brar

Since Specialization
Citations

This map shows the geographic impact of Indira Brar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Indira Brar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Indira Brar more than expected).

Fields of papers citing papers by Indira Brar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Indira Brar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Indira Brar. The network helps show where Indira Brar may publish in the future.

Co-authorship network of co-authors of Indira Brar

This figure shows the co-authorship network connecting the top 25 collaborators of Indira Brar. A scholar is included among the top collaborators of Indira Brar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Indira Brar. Indira Brar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, Emma, Carlos Malvestutto, Heather J. Ribaudo, et al.. (2025). Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort. Open Forum Infectious Diseases. 12(4). ofaf177–ofaf177.
2.
Yared, Nicholas, Smitha Gudipati, Shannon R. Payne, & Indira Brar. (2025). Assessment of Failures of Long-acting Cabotegravir and Rilpivirine in a Real-world Treatment Setting. Open Forum Infectious Diseases. 12(7). ofaf349–ofaf349. 1 indexed citations
3.
4.
Fichtenbaum, Carl J., Carlos Malvestutto, Maya Watanabe, et al.. (2025). Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis. The Lancet HIV. 12(7). e496–e505.
5.
6.
Bender, David A., et al.. (2024). 226 Prevalence of People With HIV Visiting the Emergency Department and Linkage to Care Status. Annals of Emergency Medicine. 84(4). S104–S104. 1 indexed citations
7.
Brar, Indira, et al.. (2023). 2661. Characterization of Mpox in Southeast Michigan. Open Forum Infectious Diseases. 10(Supplement_2).
8.
Yared, Nicholas, et al.. (2023). 1615. Efficacy of Long-Acting Cabotegravir and Rilpivirine in a Diverse Group of Patients in a Real-World Setting. Open Forum Infectious Diseases. 10(Supplement_2). 4 indexed citations
9.
Herc, Erica, et al.. (2022). Atypical presentation of progressive disseminated histoplasmosis in a patient recently diagnosed with AIDS. International Journal of Infectious Diseases. 127. 45–47.
10.
Kenney, Rachel M., et al.. (2022). Evaluating the Impact of Substance Use Disorder Resources on Outcomes of Persons Who Inject Drugs with Infections. Journal of Addiction Medicine. 17(1). 104–107. 1 indexed citations
11.
Gudipati, Smitha, et al.. (2021). Seroprevalence of antibodies against sars-cov-2 among people living with hiv (PLWH). 29(1). 243–243. 1 indexed citations
12.
Gudipati, Smitha, et al.. (2020). Descriptive Analysis of Patients Living With HIV Affected by COVID-19. JAIDS Journal of Acquired Immune Deficiency Syndromes. 85(2). 123–126. 25 indexed citations
13.
Brar, Indira, Peter Ruane, Douglas Ward, et al.. (2020). 1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine. Open Forum Infectious Diseases. 7(Supplement_1). S543–S544. 3 indexed citations
14.
Gallant, Joel E., Adriano Lazzarin, Anthony Mills, et al.. (2017). Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. The Lancet. 390(10107). 2063–2072. 257 indexed citations breakdown →
15.
Sax, Paul E., Andrew Zolopa, Indira Brar, et al.. (2014). Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(1). 52–58. 165 indexed citations
16.
Huamán, Moisés A., et al.. (2011). Late presentation and transmitted drug resistance mutations in new HIV-1 diagnoses in Detroit. International Journal of Infectious Diseases. 15(11). e764–e768. 11 indexed citations
17.
18.
Huamán, Moisés A., et al.. (2010). Epidemiologic characteristics and transmitted drug resistance mutation patterns among newly diagnosed HIV infected individuals in a large tertiary care hospital in Detroit. International Journal of Infectious Diseases. 14. e73–e73. 1 indexed citations
19.
Richter, Adrian, Manel Pladevall, R Manjunath, et al.. (2005). Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV‐infected patients: a retrospective cohort study. HIV Medicine. 6(2). 79–90. 24 indexed citations
20.
Gonzalez, Omar, Daniel M. Musher, Indira Brar, et al.. (2003). Spectrum of Bacille Calmette‐Guerin (BCG) Infection after Intravesical BCG Immunotherapy. Clinical Infectious Diseases. 36(2). 140–148. 144 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elena Seminari Breakdown of academic impact, for papers by Justyna Kowalska Breakdown of academic impact, for papers by Ian Woolley Breakdown of academic impact, for papers by Barry S. Zingman Breakdown of academic impact, for papers by Antoni Noguera‐Julián Breakdown of academic impact, for papers by Giuseppe Vittorio De Socio Breakdown of academic impact, for papers by Marco Floridia Breakdown of academic impact, for papers by É. Rouveix Breakdown of academic impact, for papers by Thierry May Breakdown of academic impact, for papers by Javier Martínez‐Sanz
Rankless by CCL
2026